Literature DB >> 8550193

Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus.

F De Bernardis1, P Chiani, M Ciccozzi, G Pellegrini, T Ceddia, G D'Offizzi, I Quinti, P A Sullivan, A Cassone.   

Abstract

Isolates of Candida albicans from the oral cavities of subjects at different stages of human immunodeficiency virus (HIV) infection or uninfected controls were examined for (i) production of aspartic proteinase(s), a putative virulence-associated factor(s); (ii) the presence in the fungal genome of two major genes (SAP1 and SAP2) of the aspartic proteinase family; and (iii) experimental pathogenicity in a murine model of systemic infection. It was found that the fungal isolates from symptomatic patients secreted, on average, up to eightfold more proteinase than the isolates from uninfected or HIV-infected but asymptomatic subjects. This differential property was stably expressed by the strains even after years of maintenance in stock cultures. Moreover, representative high-proteinase isolates were significantly more pathogenic for mice than low-proteinase isolates of C. albicans. The characters high proteinase and increased virulence were not associated with a single molecular type or category identifiable through DNA fingerprinting or pulsed-field electrophoretic karyotype, and both SAP1 and SAP2 genes were present in both categories of isolates, on the same respective chromosomes. In conclusion, our data suggest that during HIV infection more-virulent strains or biotypes of C. albicans which are identifiable by direct analysis of virulence determinants are selected. It also appears that the biotype switch to increased aspartic proteinase and virulence properties occurs before the HIV-infected subject enters the symptomatic stage and overt AIDS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550193      PMCID: PMC173787          DOI: 10.1128/iai.64.2.466-471.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Comparison of molecular typing methods for Candida albicans.

Authors:  P T Magee; L Bowdin; J Staudinger
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

Review 2.  High-frequency switching in Candida albicans.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 3.  Putative virulence factors of Candida albicans.

Authors:  J E Cutler
Journal:  Annu Rev Microbiol       Date:  1991       Impact factor: 15.500

4.  Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting.

Authors:  J Schmid; F C Odds; M J Wiselka; K G Nicholson; D R Soll
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

5.  Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance.

Authors:  L Romani; S Mocci; C Bietta; L Lanfaloni; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

6.  The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albicans from the oral cavity of HIV-infected subjects.

Authors:  F De Bernardis; M Boccanera; L Rainaldi; C E Guerra; I Quinti; A Cassone
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

7.  The genes encoding the secreted aspartyl proteinases of Candida albicans constitute a family with at least three members.

Authors:  B B Magee; B Hube; R J Wright; P J Sullivan; P T Magee
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

8.  Identification of a 65-kDa mannoprotein as a main target of human cell-mediated immune response to Candida albicans.

Authors:  A Torosantucci; C Bromuro; M J Gomez; C M Ausiello; F Urbani; A Cassone
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

9.  Heterogeneity of the purified extracellular aspartyl proteinase from Candida albicans: characterization with monoclonal antibodies and N-terminal amino acid sequence analysis.

Authors:  C J Morrison; S F Hurst; S L Bragg; R J Kuykendall; H Diaz; J Pohl; E Reiss
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

10.  Proliferative and cytotoxic responses to mannoproteins of Candida albicans by peripheral blood lymphocytes of HIV-infected subjects.

Authors:  I Quinti; C Palma; E C Guerra; M J Gomez; I Mezzaroma; F Aiuti; A Cassone
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

View more
  34 in total

1.  Lack of ritonavir antifungal effect in vitro.

Authors:  P Diz; A Ocampo; I Iglesias; I Otero
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis.

Authors:  J R Naglik; G Newport; T C White; L L Fernandes-Naglik; J S Greenspan; D Greenspan; S P Sweet; S J Challacombe; N Agabian
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 3.  Cell wall and secreted proteins of Candida albicans: identification, function, and expression.

Authors:  W L Chaffin; J L López-Ribot; M Casanova; D Gozalbo; J P Martínez
Journal:  Microbiol Mol Biol Rev       Date:  1998-03       Impact factor: 11.056

4.  Extracellular proteinase activity of Cryptococcus neoformans.

Authors:  L C Chen; E S Blank; A Casadevall
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

5.  High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women.

Authors:  F de Bernardis; F Mondello; G Scaravelli; A Pachì; A Girolamo; L Agatensi; A Cassone
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

Review 6.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Fluconazole versus Candida albicans: a complex relationship.

Authors:  J R Graybill; E Montalbo; W R Kirkpatrick; M F Luther; S G Revankar; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  The effect of gentian violet on virulent properties of Candida albicans.

Authors:  Su Ying; Sun Qing; Li Chunyang
Journal:  Mycopathologia       Date:  2009-11-24       Impact factor: 2.574

Review 9.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2.

Authors:  Manuel Vilanova; Luzia Teixeira; Iris Caramalho; Egídio Torrado; Andreia Marques; Pedro Madureira; Adília Ribeiro; Paula Ferreira; Miguel Gama; Jocelyne Demengeot
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.